Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Cantargia

    MCap

    SEK593m

    Last close

    SEK3.04

    ▲ 0.66 (27.46%)

    Alzinova

    MCap

    SEK139m

    Last close

    SEK1.66

    ▲ 0.34 (25.30%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Lavie Bio

Executive interview – Lavie Bio

Lavie Bio aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based ag-biological products. Using proprietary computational predictive technologies, Lavie Bio is implementing a ‘biology-driven design’ approach to introduce ‘next-generation’ bio-stimulants and bio-pesticides.

The interview features CEO Ido Dor and board member Kristian Bjørneboe.

Lavie Bio is a private subsidiary of Edison client Evogene (TASE: EVGN, NASDAQ: EVGN), a leading company in leveraging computational biology to design novel products for life science-based industries including human health, agriculture and industrial applications. To achieve its mission, Evogene established a unique Computational Predictive Biology (CPB) platform, leveraging the revolutions in big data and artificial intelligence, and incorporating a deep understanding of biology.

< Previous
Next >

You may also be interested in these:

Consumer

Card Factory – executive interview

Healthcare

SynAct Pharma – executive interview